Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.18446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Hepatitis D Screening-DAS (Delta Virus Awareness and Screening) Approach in Primary Care.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.
Editorial: Hepatitis D Screening-DAS (Delta Virus Awareness and Screening) Approach in Primary Care. Authors' Reply.
Aliment Pharmacol Ther
January 2025
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B-Authors' Reply.
Aliment Pharmacol Ther
January 2025
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.
Aliment Pharmacol Ther
January 2025
Liverpool Hospital, New South Wales, Sydney, Australia.
Revolutionizing the understanding of liver disease: Metabolism, function and future.
World J Hepatol
December 2024
Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04360, Mexico.
The intersection between metabolic-associated steatotic liver disease (MASLD) and chronic hepatitis B virus (HBV) infection is an emerging area of research with significant implications for public health and clinical practice. Wang 's study highlights the complexities of managing patients with concurrent MASLD and HBV. The findings revealed that patients with concurrent MASLD-HBV exhibited more severe liver inflammation and fibrosis, whereas those with HBV alone presented a better lipid profile.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!